

Content

Acid hydrolysis of compounds 1-7	3
α -Glucosidase inhibitory assay	4
α -Amylase inhibitory assay	4
Table S1. The α -glucosidase and α -amylase inhibitory effects of the compounds 1-13	5
Figure S1 IR spectrum of compound 1	6
Figure S2 HR-ESI-MS of compound 1	6
Figure S3 $^1\text{H-NMR}$ spectrum of compound 1 in CD_3OD	7
Figure S4 Extended $^1\text{H-NMR}$ spectrum of compound 1 in CD_3OD	8
Figure S5 $^{13}\text{C-NMR}$ spectrum of compound 1 in CD_3OD	9
Figure S6 HSQC spectrum of compound 1 in CD_3OD	10
Figure S7 HMBC spectrum of compound 1 in CD_3OD	11
Figure S8 Expanded HMBC spectrum of compound 1 in CD_3OD	12
Figure S9 COSY spectrum of compound 1 in CD_3OD	13
Figure S10 NOESY spectrum of compound 1 in CD_3OD	14
Figure S11 IR spectrum of compound 2	15
Figure S12 HR-ESI-MS of compound 2	15
Figure S13 $^1\text{H-NMR}$ spectrum of compound 2 in CD_3OD	16
Figure S14 Extended $^1\text{H-NMR}$ spectrum of compound 2 in CD_3OD	17
Figure S15 $^{13}\text{C-NMR}$ spectrum of compound 2 in CD_3OD	18
Figure S16 HSQC spectrum of compound 2 in CD_3OD	19
Figure S17 HMBC spectrum of compound 2 in CD_3OD	20
Figure S18 Expanded HMBC spectrum of compound 2 in CD_3OD	21
Figure S19 Expanded HMBC spectrum of compound 2 in CD_3OD	22
Figure S20 COSY spectrum of compound 2 in CD_3OD	23
Figure S21 NOESY spectrum of compound 2 in CD_3OD	24
Figure S22 IR spectrum of compound 3	25
Figure S23 HR-ESI-MS of compound 3	25
Figure S24 $^1\text{H-NMR}$ spectrum of compound 3 in CD_3OD	26
Figure S25 Extended $^1\text{H-NMR}$ spectrum of compound 3 in CD_3OD	27
Figure S26 $^{13}\text{C-NMR}$ spectrum of compound 3 in CD_3OD	28
Figure S27 HSQC spectrum of compound 3 in CD_3OD	29
Figure S28 HMBC spectrum of compound 3 in CD_3OD	30
Figure S29 Expanded HMBC spectrum of compound 3 in CD_3OD	31
Figure S30 COSY spectrum of compound 3 in CD_3OD	32
Figure S31 NOESY spectrum of compound 3 in CD_3OD	33
Figure S32 IR spectrum of compound 4	34
Figure S33 HR-ESI-MS of compound 4	34
Figure S34 $^1\text{H-NMR}$ spectrum of compound 4 in CD_3OD	35
Figure S35 Extended $^1\text{H-NMR}$ spectrum of compound 4 in CD_3OD	36
Figure S36 $^{13}\text{C-NMR}$ spectrum of compound 4 in CD_3OD	37
Figure S37 HSQC spectrum of compound 4 in CD_3OD	38
Figure S38 HMBC spectrum of compound 4 in CD_3OD	39
Figure S39 Expanded HMBC spectrum of compound 4 in CD_3OD	40
Figure S40 Expanded HMBC spectrum of compound 4 in CD_3OD	41
Figure S41 COSY spectrum of compound 4 in CD_3OD	42
Figure S42 NOESY spectrum of compound 4 in CD_3OD	43
Figure S43 IR spectrum of compound 5	44
Figure S44 HR-ESI-MS of compound 5	44
Figure S45 $^1\text{H-NMR}$ spectrum of compound 5 in CD_3OD	45
Figure S46 Extended $^1\text{H-NMR}$ spectrum of compound 5 in CD_3OD	46
Figure S47 $^{13}\text{C-NMR}$ spectrum of compound 5 in CD_3OD	47

Figure S48	HSQC spectrum of compound 5 in CD ₃ OD	48
Figure S49	HMBC spectrum of compound 5 in CD ₃ OD	49
Figure S50	Expanded HMBC spectrum of compound 5 in CD ₃ OD	50
Figure S51	COSY spectrum of compound 5 in CD ₃ OD	51
Figure S52	NOESY spectrum of compound 5 in CD ₃ OD	52
Figure S53	IR spectrum of compound 6	53
Figure S54	HR-ESI-MS of compound 6	53
Figure S55	¹ H-NMR spectrum of compound 6 in CD ₃ OD	54
Figure S56	Extended ¹ H-NMR spectrum of compound 6 in CD ₃ OD	55
Figure S57	¹³ C-NMR spectrum of compound 6 in CD ₃ OD	56
Figure S58	HSQC spectrum of compound 6 in CD ₃ OD	57
Figure S59	HMBC spectrum of compound 6 in CD ₃ OD	58
Figure S60	Expanded HMBC spectrum of compound 6 in CD ₃ OD	59
Figure S61	COSY spectrum of compound 6 in CD ₃ OD	60
Figure S62	NOESY spectrum of compound 6 in CD ₃ OD	61
Figure S63	IR spectrum of compound 7	62
Figure S64	HR-ESI-MS of compound 7	62
Figure S65	¹ H-NMR spectrum of compound 7 in CD ₃ OD	63
Figure S66	Extended ¹ H-NMR spectrum of compound 7 in CD ₃ OD	64
Figure S67	¹³ C-NMR spectrum of compound 7 in CD ₃ OD	65
Figure S68	HSQC spectrum of compound 7 in CD ₃ OD	66
Figure S69	HMBC spectrum of compound 7 in CD ₃ OD	67
Figure S70	Expanded HMBC spectrum of compound 7 in CD ₃ OD	68
Figure S71	Expanded HMBC spectrum of compound 7 in CD ₃ OD	69
Figure S72	COSY spectrum of compound 7 in CD ₃ OD	70
Figure S73	NOESY spectrum of compound 7 in CD ₃ OD	71
Figure S74	¹ H-NMR spectrum of compound 8 in CD ₃ OD	72
Figure S75	¹³ C-NMR spectrum of compound 8 in CD ₃ OD	72
Figure S76	¹ H-NMR spectrum of compound 9 in CD ₃ OD	73
Figure S77	¹³ C-NMR spectrum of compound 9 in CD ₃ OD	73
Figure S78	¹ H-NMR spectrum of compound 10 in CD ₃ OD	74
Figure S79	¹³ C-NMR spectrum of compound 10 in CD ₃ OD	74
Figure S80	¹ H-NMR spectrum of compound 11 in CD ₃ OD	75
Figure S81	¹³ C-NMR spectrum of compound 11 in CD ₃ OD	75
Figure S82	¹ H-NMR spectrum of compound 12 in CD ₃ OD	76
Figure S83	¹³ C-NMR spectrum of compound 12 in CD ₃ OD	76
Figure S84	¹ H-NMR spectrum of compound 13 in CD ₃ OD	77
Figure S85	¹³ C-NMR spectrum of compound 13 in CD ₃ OD	77

Acid hydrolysis of compounds 1-7

Compounds **1-7** (each, 5.0 mg) were separately dissolved in 1.0 M HCl (dioxane–H₂O, 1:1, v/v, 1.0 mL) and heated to 80 °C in a water bath for 3 h. For each compound, the acidic solution was neutralized with silver carbonate, the precipitated silver chloride was removed, and the solution was concentrated thoroughly under a nitrogen atmosphere. The residue was re-dissolved in 1.0 mL of water and extracted with chloroform (three times, each 1 mL). The aqueous layer was concentrated to dryness using nitrogen gas and monosaccharides were purified by preparative TLC (pre-coated silica gel 60 F₂₅₄, MeCOEt–isoPrOH–Me₂CO–H₂O (20:10:7:6). The specific rotations $[\alpha]_D^{25}$ of sugars were determined after dissolving in H₂O.

For compound **1**: glucose (1.2 mg, R_f = 0.42, $[\alpha]_D^{25}$ +48.0), arabinose (0.8 mg, R_f = 0.48, $[\alpha]_D^{25}$ +42.0), rhamnose (0.8 mg, R_f = 0.65, $[\alpha]_D^{25}$ +18.0).

For compound **2**: glucose (1.3 mg, R_f = 0.42, $[\alpha]_D^{25}$ +47.0), arabinose (0.7 mg, R_f = 0.48, $[\alpha]_D^{25}$ +41.0), rhamnose (0.8 mg, R_f = 0.65, $[\alpha]_D^{25}$ +19.0).

For compound **3**: glucose (1.2 mg, R_f = 0.42, $[\alpha]_D^{25}$ +47.0), arabinose (0.8 mg, R_f = 0.48, $[\alpha]_D^{25}$ +41.5), rhamnose (0.9 mg, R_f = 0.65, $[\alpha]_D^{25}$ +19.0).

For compound **4**: glucose (1.2 mg, R_f = 0.42, $[\alpha]_D^{25}$ +48.5), arabinose (0.8 mg, R_f = 0.48, $[\alpha]_D^{25}$ +41.5), rhamnose (0.8 mg, R_f = 0.65, $[\alpha]_D^{25}$ +18.0).

For compound **5**: glucose (1.2 mg, R_f = 0.42, $[\alpha]_D^{25}$ +48.0), arabinose (0.8 mg, R_f = 0.48, $[\alpha]_D^{25}$ +42.0), rhamnose (0.8 mg, R_f = 0.65, $[\alpha]_D^{25}$ +18.0).

For compound **6**: glucose (1.3 mg, R_f = 0.42, $[\alpha]_D^{25}$ +48.0), arabinose (0.8 mg, R_f = 0.48, $[\alpha]_D^{25}$ +41.0), rhamnose (0.9 mg, R_f = 0.65, $[\alpha]_D^{25}$ +18.0).

For compound **7**: glucose (1.3 mg, R_f = 0.42, $[\alpha]_D^{25}$ +48.0), arabinose (0.9 mg, R_f = 0.48, $[\alpha]_D^{25}$ +41.0).

α -Glucosidase inhibitory assay

The α -glucosidase (G0660, Sigma-Aldrich, St. Louis, MO) enzyme inhibition assay was performed according to the previously described method. In brief, 20 μ L of sample solution and 40 μ L of α -glucosidase solution were well mixed with 100 μ L of 0.1 M phosphate buffer (pH 7.0) in a 96-well plate. After 5 min pre-incubation at 37 °C, the substrate, *p*-nitrophenyl- α -D-glucopyranoside solution (40 μ L) was added, and the reaction mixture was incubated at 37 °C for 30 min. The absorbance of was then measured at 405 nm by using an ELISA Bio-Rad microplate reader. Reaction mixture containing acarbose solution instead of sample solution was used as positive control. And reaction mixture containing buffer solution instead of sample solution was used as negative control.

α -Amylase inhibitory assay

The α -amylase (A3176, Sigma-Aldrich, St. Louis, MO) enzyme inhibitory activity was measured using the reported method. Substrate was prepared by boiling 100 mg potato starch in 5 mL phosphate buffer (pH 7.0) for 5 min, then cooling to room temperature. The sample solution (20 μ L) and substrate (30 μ L) were mixed with 30 μ L of 0.1 M phosphate buffer (pH 7.0). After 5 min pre-incubation, 20 μ L of α -amylase solution was added and the reaction mixture was incubated at 37°C for 15 min. The reaction was stopped by adding 50 μ L HCl 1 M and then 50 μ L iodine solution. The absorbances were then measured at 650 nm by a microplate reader. Reaction mixture containing acarbose solution instead of sample solution was used as positive control. And reaction mixture containing buffer solution instead of sample solution was used as negative control.

Table S1. The α -glucosidase and α -amylase inhibitory effects of the compounds **1-13** (200 μ M)

Comp.	α -glucosidase inhibition (%)		α -amylase inhibition (%)	
	Mean	SD	Mean	SD
1	94.65	2.19	88.29	2.50
2	82.25	1.87	85.03	1.84
3	84.26	1.59	92.42	1.86
4	81.48	2.42	91.11	2.51
5	64.73	2.64	31.91	1.72
6	60.81	2.37	64.46	1.80
7	55.34	1.38	44.92	2.94
8	92.68	1.12	94.22	1.57
9	90.95	1.23	83.88	2.25
10	67.98	1.20	48.04	2.32
11	53.62	1.15	62.71	2.06
12	46.36	2.36	69.74	2.20
13	42.20	2.70	57.38	2.64
Acarbose*	84.05	2.58	61.23	2.15

[*]Acarbose was used as a positive control (at 100 μ g/mL ~ 155 μ M). Experiments were performed in triplicate.





Figure S1. IR spectrum of compound 1



HR-ESI-MS m/z : 1227.5586 [M+Na]⁺, (calcd. for [C₆₁H₈₈O₂₄Na]⁺, 1227.5558, Δ =+2.3 ppm); m/z : 1205.5728 [M+H]⁺, (calcd. for [C₆₁H₈₉O₂₄]⁺, 1205.5739, Δ =-0.9 ppm).

Figure S2. HR-ESI-MS of compound 1





Figure S4. Extended ^1H -NMR spectrum of compound 1 in CD_3OD







Figure S6. HSQC spectrum of compound 1 in CD₃OD





Figure S7. HMBC spectrum of compound **1** in CD₃OD




Figure S8. Expanded HMBC spectrum of compound **1** in CD₃OD




Figure S9. COSY spectrum of compound 1 in CD₃OD




Figure S10. NOESY spectrum of compound 1 in CD₃OD




Figure S11. IR spectrum of compound 2




Figure S12. HR-ESI-MS of compound 2




Figure S13. ¹H-NMR spectrum of compound 2 in CD₃OD




Figure S14. Extended $^1\text{H-NMR}$ spectrum of compound **2** in CD_3OD







Figure S15. ^{13}C -NMR spectrum of compound **2** in CD_3OD






Figure S16. HSQC spectrum of compound **2** in CD_3OD





Figure S17. HMBC spectrum of compound **2** in CD₃OD





Figure S18. Extended HMBC spectrum of compound **2** in CD₃OD





Figure S19. Extended HMBC spectrum of compound **2** in CD₃OD




Figure S20. COSY spectrum of compound **2** in CD₃OD




Figure S21. NOESY spectrum of compound **2** in CD₃OD




Figure S22. IR spectrum of compound 3




Figure S23. HR-ESI-MS spectrum of compound 3




Figure S24. ^1H NMR spectrum of compound **3** in CD_3OD




Figure S25. Extended ^1H NMR spectrum of compound 3 in CD_3OD






Figure S26. ^{13}C NMR spectrum of compound **3** in CD_3OD






Figure S27. HSQC spectrum of compound 3 in CD₃OD






Figure S28. HMBC spectrum of compound **3** in CD₃OD




Figure S29. Extended HMBC spectrum of compound 3 in CD₃OD




Figure S30. COSY spectrum of compound **3** in CD₃OD




Figure S31. NOESY spectrum of compound **3** in CD₃OD






Figure S32. IR spectrum of compound 4



HR-ESI-MS m/z 1235.5839 [M-H]⁻, (calcd. for [C₆₂H₉₁O₂₅]⁻), 1235.5855, Δ=-1.3 ppm), m/z 1271.5568 [M+³⁵Cl]⁺, (calcd. for [C₆₂H₉₂O₂₅³⁵Cl]⁺), 1271.5521, Δ=-4.2 ppm), m/z 1273.5563 [M+³⁷Cl]⁺, (calcd. for [C₆₂H₉₂O₂₅³⁷Cl]⁺), 1273.5592, Δ=-2.3 ppm)

Figure S33. HR-ESI-MS spectrum of compound 4




Figure S34. ¹H NMR spectrum of compound 4 in CD₃OD




Figure S35. Extended ^1H NMR spectrum of compound **4** in CD_3OD




Figure S36. ^{13}C NMR spectrum of compound **4** in CD_3OD





Figure S37. HSQC spectrum of compound 4 in CD₃OD





Figure S38. HMBC spectrum of compound 4 in CD₃OD





Figure S39. Extended HMBC spectrum of compound 4 in CD₃OD





Figure S40. Extended HMBC spectrum of compound 4 in CD₃OD




Figure S41. COSY spectrum of compound **4** in CD₃OD




Figure S42. NOESY spectrum of compound 4 in CD₃OD





Figure S43. IR spectrum of compound **5**



HR-ESI-MS m/z 1075.5679 $[M+H]^+$, (calcd. for $[C_{53}H_{87}O_{22}]^+$, 1075.5684, $\Delta=-0.5$ ppm), m/z 1097.5476 $[M+Na]^+$, (calcd. for $[C_{53}H_{86}O_{22}Na]^+$, 1097.5503, $\Delta=-2.5$ ppm)

Figure S44. HR-ESI-MS spectrum of compound **5**





Figure S45. ^1H NMR spectrum of compound 5 in CD_3OD




Figure S46. Extended ^1H NMR spectrum of compound **5** in CD_3OD





Figure S47. ^{13}C NMR spectrum of compound **5** in CD_3OD






Figure S48. HSQC spectrum of compound **5** in CD₃OD





Figure S49. HMBC spectrum of compound 5 in CD₃OD





Figure S50. Extended HMBC spectrum of compound 5 in CD₃OD




Figure S51. COSY spectrum of compound **5** in CD₃OD




Figure S52. NOESY spectrum of compound 5 in CD₃OD





Figure S53. IR spectrum of compound 6



HR-ESI-MS m/z 1061.5553 $[M+H]^+$, (calcd. for $[C_{52}H_{85}O_{22}]^+$, 1061.5527, $\Delta=+2.5$ ppm), m/z 1083.5373 $[M+Na]^+$, (calcd. for $[C_{52}H_{84}O_{22}Na]^+$, 1083.5347, $\Delta=+2.4$ ppm)

Figure S54. HR-ESI-MS spectrum of compound 6




Figure S55. ^1H NMR spectrum of compound **6** in CD_3OD






Figure S56. Extended ^1H NMR spectrum of compound **6** in CD_3OD







Figure S57. ^{13}C NMR spectrum of compound **6** in CD_3OD






Figure S58. HSQC spectrum of compound **6** in CD₃OD





Figure S59. HMBC spectrum of compound **6** in CD₃OD





Figure S60. Extended HMBC spectrum of compound **6** in CD₃OD




Figure S61. COSY spectrum of compound **6** in CD₃OD




Figure S62. NOESY spectrum of compound 6 in CD₃OD





Figure S63. IR spectrum of compound 7



HR-ESI-MS m/z 929.5128 $[M+H]^+$, (calcd. for $[C_{47}H_{77}O_{18}]^+$, 929.5105, $\Delta=+2.5$ ppm), m/z 951.4913 $[M+Na]^+$, (calcd. for $[C_{47}H_{76}O_{18}Na]^+$, 951.4924, $\Delta=-1.7$ ppm)

Figure S64. HR-ESI-MS spectrum of compound 7




Figure S65. ^1H NMR spectrum of compound 7 in CD_3OD




Figure S66. Extended ^1H NMR spectrum of compound 7 in CD_3OD




Figure S67. ^{13}C NMR spectrum of compound 7 in CD_3OD





Figure S68. Extended ^{13}C NMR spectrum of compound 7 in CD_3OD





Figure S69. HSQC spectrum of compound 7 in CD₃OD




Figure S70. HMBC spectrum of compound 7 in CD₃OD





Figure S71. Extended HMBC spectrum of compound 7 in CD₃OD





Figure S72. Extended HMBC spectrum of compound 7 in CD₃OD




Figure S73. COSY spectrum of compound 7 in CD₃OD





Figure S74. NOESY spectrum of compound 7 in CD₃OD




Figure S75. ¹H-NMR spectrum of compound **8** in CD₃OD




Figure S76. ¹³C-NMR spectrum of compound **8** in CD₃OD




Figure S77. ¹H-NMR spectrum of compound 9 in CD₃OD




Figure S78. ¹³C-NMR spectrum of compound 9 in CD₃OD




Figure S79. ¹H-NMR spectrum of compound 10 in CD₃OD




Figure S80. ¹³C-NMR spectrum of compound 10 in CD₃OD




Figure S81. ¹H-NMR spectrum of compound **11** in CD₃OD




Figure S82. ¹³C-NMR spectrum of compound **11** in CD₃OD




Figure S83. ¹H-NMR spectrum of compound 12 in CD₃OD




Figure S84. ¹³C-NMR spectrum of compound 12 in CD₃OD




Figure S85. $^1\text{H-NMR}$ spectrum of compound 13 in CD_3OD




Figure S86. $^{13}\text{C-NMR}$ spectrum of compound 13 in CD_3OD